Program Details

On Demand

The following presentations will be available to watch on-demand from January 18 – January 30, 2022, plus 30 days post-meeting (until February 28, 2022):

Children With Outbursts: Who Are They, What Happens to Them, and What Can We Do About Them? 
Gabrielle A. Carlson, MD
Serious emotional outbursts are not confined to one diagnosis. In this presentation, Dr. Carlson discusses how to evaluate them, their differential diagnosis, and summarizes our current knowledge base about how to treat them in outpatient and other settings. 

Practical Approaches to ADHD Pharmacotherapy: What’s Easy, What’s New, What’s Complicated 
James J. McGough, MD
This presentation provides an overview of approaches to managing simple and complicated cases of ADHD, including consideration of long-standing and new medication options, as well as strategies for addressing comorbidities and side effects. Lecture content provides a basis for small group discussion and consultation on difficult medication issues presented by attendees.

Clinical Pearls for the Pharmacological Management of Pediatric Bipolar Disorder 
Boris Birmaher, MD
Dr. Birmaher discusses how to correctly diagnose youths with bipolar disorder to ensure successful treatment, and reviews the pros and cons of current evidence-based treatments.


Tics, Twitches, and More: Update on Tools for our Medication Toolkits
Barbara Coffey, MD, MS
Child and adolescent psychiatrists are frequently called upon to evaluate abnormal movements in the context of pediatric psychiatric evaluation. Typical movement disorders range from tics and stereotypies to choreiform and functional movements in children. This presentation addresses the challenges of differential diagnosis of abnormal movements in children and adolescent and highlights established and potentially new treatment options.

New Psychotropic Agents 
Robert Findling, MD, MBA
This presentation focuses on several new agents that have received FDA approved for a broad variety of psychiatric indications and may be informative in future medication selection decisions. These drugs have efficacy in adults; however, it should be remembered that these agents have generally not been studied in children and adolescents.

Pharmacotherapies for Early Onset Psychosis and Psychotic Symptoms 
Jon McClellan, MD
Learn about the differential diagnosis and treatment of psychosis in children and adolescents. Dr. McClellan reviews the current evidence supporting the use of antipsychotic agents in youth with psychotic illnesses, and standard guidelines for prescribing and monitoring these agents in the pediatric population.

Advanced Pharmacotherapy for Pediatric Depression 
Jeffrey R. Strawn, MD
Significant advances have been made in the treatment of pediatric depressive disorders, including treatment-resistant major depressive disorder. Moreover, accumulating data suggest practical strategies to tailor treatments to individual patients. This presentation reviews recent studies that help to answer (1) How can we predict which patients may respond fastest to SSRIs or SSRIs + cognitive behavioral therapy? (2) When should treatment be changed? (3) Is there evidence for adjunctive pharmacotherapy in youth with MDD?

Pharmacotherapy in Autism Spectrum Disorder and Intellectual Disability (Intellectual Developmental Disorder) 
Jeremy Veenstra-VanderWeele, MD
Dr. Veesntra-VanderWeele discusses the evidence and lack of evidence for medication treatments in autism spectrum disorder and intellectual disability. The presentation then transitions to a world-world management perspective, providing practice pathways for assessment and treatment of common problems presenting in children, adolescents, and adults with developmental disorders. Vignettes are used as examples to highlight key points.

Update on the Treatment of Pediatric Anxiety Disorders 
John Walkup, MD
Anxiety disorders are arguably the most common psychiatric disorder affecting children and adolescents. Despite high prevalence, prepubertal onset and a strong treatment evidence base the anxiety disorders are often not identified and not treated effectively, leaving children and adolescents at risk for poor long-term coping and adaptation, depression, substance use and self-injury. This presentation addresses the diagnostic assessment of the anxiety disorders, how to avoid misdiagnosis, how to facilitate early patient and family engagement, how to develop a tiered treatment plan, and how to manage patients who do not respond to pharmacological and psychological treatment as expected.

Key Components of Substance Use Disorder Treatment for the Child Psychiatrist 
Amy Yule, MD
Learn about the key components to review when evaluating an adolescent with a substance use disorder. Dr. Yule reviews recommended treatment for adolescents with a substance use disorder with a focus on pharmacologic treatments for substance use disorders with and without a co-occurring psychiatric disorder. 

 

Virtual Live Sessions

The following is the schedule of Virtual Live Sessions January 29 – January 30:

 

Day/Time

Session

Speaker(s)

Saturday, January 29

   

12:00 pm-1:30 pm EST

Q&A Discussion

  • Boris Birmaher, MD
  • Gabrielle A. Carlson, MD
  • Barbara Coffey, MD, MS
  • Jon McClellan, MD
  • Jeremy Veenstra-VanderWeele, MD
  • James J. McGough, MD, Moderator

2:00 pm-3:00 pm EST

Case Consultation Sessions

All speakers – see presentation topics above

3:30 pm-4:30 pm EST

Case Consultation Sessions

All speakers – see presentation topics above

 

 

 

Sunday, January 30

 

 

12:00 pm-1:30 pm EST

Q&A Discussion

  • Robert Findling, MD, MBA
  • James J. McGough, MD
  • Jeffrey R. Strawn, MD
  • John Walkup, MD
  • Amy Yule, MD
  • Gabrielle A. Carlson, MD, Moderator

2:00 pm-3:00 pm EST

Case Consultation Sessions

All speakers – see presentation topics above

3:30 pm-4:30 pm EST

Case Consultation Sessions

All speakers – see presentation topics above